SOURCE: INVO Bioscience, Inc.

February 08, 2010 08:30 ET

INVO Bioscience Announces the National Institute of Health and World Health Organization Approval of a 3 Site Clinical Trial

BEVERLY, MA--(Marketwire - February 8, 2010) - INVO Bioscience, Inc. (OTCBB: IVOB), a medical device company focused on treatment options for patients diagnosed with infertility, announces that the US National Institute of Health (NIH) and the World Health Organization (WHO) has approved a 100 patient study being conducted by Galaxy IVF in three INVO centers in Pakistan. The purpose of the study is to evaluate a low cost stimulation protocol combined with INVO to make an IVF affordable procedure available across the large infertile/sub-fertile population. The study will use a minimum ovarian stimulation protocol with the primary endpoint being number of follicles obtained and the fertilization rate. The secondary endpoints will be pregnancy rate and cost of treatment.

Recruitment has begun for the study and Dr. Ranoux will be attending the first INVO cycles at each of the clinical sites.

Galaxy IVF has discontinued the original study started in the IVF center in Lahore because of major protocol violations by the site. The new study will be performed in INVO centers that have been trained and have already performed INVO cycles per the protocols outlined in the INVOcell Instructions for Use.

This additional data will support the widespread acceptance of the INVO in the Middle East.

The approved protocol can be reviewed at the NIH site link:

or the WHO site link:

About INVO Bioscience

INVO Bioscience (IVOB) is a medical device company, headquartered in Beverly, Massachusetts, focused on creating simplified, lower cost treatment options for patients diagnosed with infertility. The company's lead product, the INVOcell, is a novel medical device used in infertility treatment that enables egg fertilization and early embryo development in the woman's vaginal cavity. The company was founded by Claude Ranoux, MD, a noted expert in the field of reproductive health, infertility and embryology. For more information, please visit

This release includes forward-looking statements within the meaning of Section 27A of the Securities Act of 1933, as amended, and Section 21E of the Securities Exchange Act of 1934, as amended. All statements regarding our expected future financial position, results of operations, cash flows, financing plans, business strategies, products and services, competitive positions, growth opportunities, plans and objectives of management for future operations, as well as statements that include words such as "anticipate," "if," "believe," "plan," "estimate," "expect," "intend," "may," "could," "should," "will," and other similar expressions are forward-looking statements. All forward-looking statements involve risks, uncertainties and contingencies, many of which are beyond our control, which may cause actual results, performance, or achievements to differ materially from anticipated results, performance, or achievements. Factors that may cause actual results to differ materially from those in the forward-looking statements include those set forth in our filings at  We are under no obligation to (and expressly disclaim any such obligation to) update or alter our forward-looking statements, whether as a result of new information, future events or otherwise. 

Contact Information